Royalty Pharma (RPRX)

This week's dividend increases feature three Dividend Kings: Archer-Daniels-Midland, Consolidated Edison, and Black Hills Corporation, with streaks of 50, 51, and 55 years, respectively. Consistently ...

Royalty Pharma's Q4 results show portfolio receipts of $742 million and operating cash flow of $678 million, which demonstrate solid performance. MorphoSys bond redeployment further enhances higher-re...

Royalty Pharma plc (NASDAQ:RPRX ) Q4 2024 Earnings Conference Call February 11, 2024 8:30 AM ET Company Participants George Grofik - SVP, Head, Investor Relations and Communications Pablo Legorreta - ...

The headline numbers for Royalty Pharma (RPRX) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Stree...

PLBC, BUSE, LKFN and RPRX recently announced dividend hikes.

The mean of analysts' price targets for Royalty Pharma (RPRX) points to a 31.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among a...

Key strategic updates include acquiring RP Management LLC, simplifying the corporate structure, reducing costs, and enhancing shareholder alignment. A new $3 billion share repurchase program and a 5% ...

Royalty Pharma (RPRX) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, RPRX crossed above the 200-day moving average, suggesti...

Royalty Pharma said on Friday it would pay about $1.1 billion to acquire RP Management, an organization that manages its operations as the healthcare firm seeks to simplify corporate structure.

As we enter the tail end of 2024, which has been a great year for the markets, as the S&P 500 has rallied by 27.35% since the beginning of the year, one question lies on the minds of investors the wor...